Cyxone’s executive management team consists of experienced experts with solid knowledge in the fields of drug development, business development and financing in innovative biotech companies.

Carl-Magnus Högerkorp

Interim CEO & COO

Born 1970. Interim CEO since 2022 and COO since 2021.


Carl-Magnus Högerkorp holds a PhD in immunology from Lund University, as well as an MBA from EFL/Lund school of Economics and Management. He brings long and broad experience from pharma and biotech companies, both internationally and nationally. During his career, Dr Högerkorp has for example worked with research and development projects within infectious disease, immuno oncology, regenerative medicine, inflammation and autoimmune diseases. Further, he has held senior positions in several companies such as CEO for Edvince, Canimguide Therapeutics and ImModulate Pharma and CSO at Xintela, where he took part in the introduction of the company on Nasdaq First North Growth Market.

Shares in the company

No shares

Henrik Hang


Born 1982. CFO since 2021.


Henrik Hang holds a B.Sc. in Business Administration. He has many years of experience as CFO and multiple finance positions in international companies and listed organizations in Sweden. Further, he has experience of listing company and fundraising.

Shares in the company

Henrik Hang owns 22,860 shares in Cyxone.


Rhea Rodeo

Office Manager/CEO assistant

Rhea Rodeo has many years of work experience as HR assistant, Secretary, Administrator, and Project Administrator. Before joining Cyxone, she worked at large international companies in Sweden, such as Westinghouse and IKEA. At Cyxone, Rhea Rodeo is responsible for general administration and provides support and assistance to the CEO and CFO.

Phone: +46 708 88 21 72